Azathioprine Unveiled
A comprehensive analysis of this vital immunosuppressive medication, exploring its mechanisms, diverse clinical applications, and critical considerations for patient management.
What is AZA? ๐ Explore Science ๐ฌDive in with Flashcard Learning!
๐ฎ Play the Wiki2Web Clarity Challenge Game๐ฎ
Overview
Immunosuppressive Agent
Azathioprine, widely recognized by brand names such as Imuran, is a potent immunosuppressive medication. Its primary function is to dampen the body's immune response, making it invaluable in clinical scenarios where immune activity needs to be modulated. This includes preventing organ rejection following transplantation and managing a spectrum of autoimmune diseases where the immune system mistakenly attacks the body's own tissues.
Administration & Side Effects
This medication can be administered orally or intravenously, offering flexibility in clinical settings. While generally effective, common adverse effects include bone-marrow suppression, which can lead to reduced blood cell counts, and gastrointestinal disturbances such as vomiting. A critical consideration is that bone-marrow suppression is particularly pronounced in individuals with a genetic deficiency in the thiopurine S-methyltransferase (TPMT) enzyme, necessitating careful patient monitoring.
Mechanism & Significance
Azathioprine belongs to the purine analogue subclass of antimetabolites. Its therapeutic action is mediated through its conversion to 6-thioguanine, which then interferes with the synthesis of essential nucleic acids, RNA and DNA, within cells. This disruption primarily affects rapidly dividing cells, including immune cells, thereby achieving its immunosuppressive effect. First synthesized in 1957, Azathioprine is listed on the World Health Organization's List of Essential Medicines, underscoring its global importance in healthcare.
Uses
Transplantation & Autoimmunity
Azathioprine is a cornerstone in preventing organ rejection after kidney or liver transplantation, often used in conjunction with other immunosuppressants like corticosteroids. Its ability to modulate the immune system makes it crucial for maintaining allograft survival. Beyond transplantation, it is extensively used to treat a variety of autoimmune conditions, including rheumatoid arthritis, pemphigus, systemic lupus erythematosus, Behรงet's disease, various forms of vasculitis, autoimmune hepatitis, atopic dermatitis, myasthenia gravis, and neuromyelitis optica.
Inflammatory Bowel Disease
In inflammatory bowel disease (IBD), Azathioprine plays a significant role in managing moderate to severe chronically active Crohn's disease. It is particularly valuable for maintaining clinical remission in corticosteroid-dependent patients and can benefit those with fistulizing Crohn's disease. However, its onset of action is notably slow, often requiring several months to achieve a full clinical response. It is also employed to prevent flares in ulcerative colitis, another form of IBD.
Other Indications
Azathioprine serves as an add-on or "steroid-sparing" agent in conditions like systemic lupus erythematosus, pemphigus, and myasthenia gravis, allowing for reduced steroid doses and their associated side effects. It is also used to maintain remission in granulomatosis with polyangiitis. While not a first-line treatment, it can be effective in severe cases of eczema and atopic dermatitis. Historically, it was used for multiple sclerosis, and while concerns about malignancy have reduced its widespread use, it remains an option for maintenance therapy in frequently relapsing patients. Notably, a 2012 study indicated that a combination therapy including azathioprine for idiopathic pulmonary fibrosis yielded worse outcomes than placebo, highlighting the importance of evidence-based practice.
Adverse
Common Side Effects
Nausea and vomiting are frequently reported, especially at the initiation of therapy; these can often be mitigated by taking the medication after meals or through temporary intravenous administration. Other hypersensitivity reactions may include dizziness, diarrhea, fatigue, and skin rashes. Hair loss, while common in transplant patients, is rare in other indications. Due to its bone marrow suppressive effects, patients are at risk of developing anemia and increased susceptibility to infections, necessitating regular monitoring of blood counts.
Carcinogenic Risk
Azathioprine is classified as a Group 1 human carcinogen by the International Agency for Research on Cancer and is listed as a known human carcinogen by the U.S. National Toxicology Program. Since 2009, the U.S. FDA has mandated warnings regarding an increased risk of certain cancers associated with its use. This risk appears to be dose- and duration-dependent. Patients previously treated with alkylating agents may face an even higher risk of malignancy when subsequently treated with Azathioprine.
Specific Malignancies
The use of Azathioprine has been linked to an increased incidence of non-Hodgkin lymphoma, squamous cell carcinomas of the skin, hepatobiliary carcinomas, and mesenchymal tumors. A particularly aggressive and often fatal form of lymphoma, hepatosplenic T-cell lymphoma, has been reported, predominantly in adolescents and young adult males with inflammatory bowel disease receiving Azathioprine. Furthermore, in transplant patients, skin cancer incidence is significantly elevated (50 to 250 times higher than the general population), with 60-90% of patients affected two decades post-transplantation. This is partly attributed to Azathioprine causing the accumulation of 6-thioguanine in DNA, which can become mutagenic upon exposure to UVA light, rendering patients abnormally sensitive to UV radiation.
Pharmacogenetics & Monitoring
The enzyme thiopurine S-methyltransferase (TPMT) plays a crucial role in the metabolism of Azathioprine. Genetic variations in the *TPMT* gene can lead to decreased or absent enzyme activity, resulting in higher levels of active thioguanine nucleotide (TGN) metabolites and a significantly increased risk of severe myelosuppression. Approximately 0.25% of patients are homozygous for these variants. Therefore, testing for TPMT activity or performing a *TPMT* genetic test is recommended to identify at-risk patients, allowing for dose adjustments or alternative therapies. Additionally, a missense SNP in *NUDT15* (e.g., rs116855232) has been identified as a causal factor for Azathioprine-induced leukopenia in East Asian populations, further highlighting the importance of pharmacogenetic considerations in personalized medicine.
Overdose
Acute vs. Chronic
Interestingly, large, single doses of Azathioprine are generally well-tolerated. For instance, a patient who ingested a massive 7.5 grams (equivalent to 150 tablets) experienced only vomiting, a slight decrease in white blood cell count, and minor changes in liver function, without severe acute toxicity. However, the primary concerns with overdose arise from prolonged exposure. Chronic overdosing manifests as consequences of its bone-marrow suppressive effects, leading to infections of unclear origin, persistent mouth ulcers, and spontaneous bleeding episodes. These symptoms underscore the importance of careful long-term dosing and monitoring rather than immediate acute toxicity concerns.
Interact
Drug Interactions
Azathioprine's metabolism can be significantly affected by other medications. For example, allopurinol, a purine analogue used to treat gout, inhibits xanthine oxidase, an enzyme responsible for breaking down Azathioprine. This inhibition can lead to increased levels of Azathioprine and its active metabolites, thereby enhancing its toxicity. Paradoxically, low doses of allopurinol have been shown to safely improve Azathioprine's efficacy, particularly in inflammatory bowel disease patients who do not respond well to standard therapy. This combination, however, necessitates meticulous monitoring due to potential risks of lower lymphocyte counts and increased infection rates.
Other Notable Interactions
Azathioprine can also influence the effects of other drugs. It has been observed to decrease the anticoagulant effect of warfarin, potentially increasing the risk of blood clots. Conversely, it can decrease the effects of non-depolarizing muscle relaxants while increasing the effects of depolarizing muscle relaxants, which is a critical consideration during surgical procedures. Furthermore, there has been a reported case where Azathioprine interfered with niacin (vitamin B3) metabolism, leading to pellagra and fatal medullary aplasia, highlighting the complexity of its drug interactions.
Pregnancy
Fetal Risks
Azathioprine carries significant risks during pregnancy, with studies indicating its potential to cause birth defects. A population-based study in Denmark, for instance, revealed a seven-fold increase in fetal abnormalities and a twenty-fold increase in miscarriage rates associated with Azathioprine and related mercaptopurine use. Reports also exist of birth defects in children whose fathers were taking Azathioprine. While well-controlled human studies are limited, animal studies at equivalent human dosages have demonstrated teratogenic effects. Despite these risks, transplant patients already on Azathioprine are generally advised *not* to discontinue the drug upon becoming pregnant, as the risks of organ rejection often outweigh the potential fetal harm. This contrasts with newer immunosuppressants like tacrolimus and mycophenolate, which are typically contraindicated during pregnancy.
Breastfeeding Considerations
Traditionally, manufacturers of cytotoxic drugs like Azathioprine advise against breastfeeding while on the medication due to potential risks to the infant. However, some pharmacological resources, such as Thomas Hale's "Medications and Mothers' Milk," classify Azathioprine as "L3" or "moderately safe" for lactation. This indicates that while there may be some concern, the potential benefits of breastfeeding might, in certain clinical scenarios, be considered against the risks, requiring careful medical consultation and individualized assessment.
Pharmacology
Pharmacokinetics: Absorption & Metabolism
Azathioprine is absorbed from the gastrointestinal tract with approximately 88% efficiency. However, its bioavailability can vary significantly among individuals (30-90%) due to partial inactivation in the liver. Peak blood plasma concentrations, including both the parent drug and its metabolites, are typically reached within 1-2 hours. The average plasma half-life for Azathioprine itself is relatively short (26-80 minutes), while the combined half-life of the drug and its active metabolites extends to 3-5 hours. Approximately 20-30% of the drug is bound to plasma proteins during circulation. The majority of the drug (98%) is excreted via the kidneys, primarily as metabolites.
Prodrug Conversion Pathway
Azathioprine functions as a prodrug, meaning it is inactive in its original form and requires metabolic conversion within the body to exert its therapeutic effects. The initial and crucial step involves its slow and almost complete conversion to 6-mercaptopurine (6-MP) through a reductive cleavage of its thioether bond. This process is non-enzymatic, facilitated by intracellular compounds like glutathione, occurring in the intestinal wall, liver, and red blood cells. 6-MP then undergoes further metabolism, analogous to natural purines, leading to the formation of active thioguanosine triphosphate (TGTP) and thiodeoxyguanosine triphosphate (TdGTP) via thioinosine monophosphate (TIMP) and other intermediates. A secondary metabolic pathway involves the methylation of 6-MP and TIMP, leading to inactive metabolites. The ultimate metabolic end products, such as thiouric acid and various methylated and hydroxylated purines, are subsequently excreted in the urine.
Mechanism of Action: Immunosuppression
The immunosuppressive action of Azathioprine stems from its ability to inhibit purine synthesis. Purines are fundamental building blocks required for the synthesis of DNA and RNA, which are essential for cell proliferation and function. By disrupting purine synthesis, Azathioprine effectively reduces the production of new DNA and RNA, particularly impacting rapidly dividing cells such as white blood cells (lymphocytes), which are central to immune responses. The active thiopurine nucleotides, formed from 6-MP, are incorporated into newly synthesized DNA, rendering it non-functional and halting replication. Furthermore, these nucleotides act as competitive inhibitors of glutamine-phosphoribosyl pyrophosphate amidotransferase (GPAT), a key enzyme in the early stages of purine biosynthesis, through a negative feedback mechanism known as product inhibition. This selective targeting of actively replicating cells, including cancer cells and activated T and B lymphocytes of the immune system, explains its efficacy in both chemotherapy (historically) and immunosuppression. Additionally, some triphosphate forms of these nucleotides bind to GTP-binding protein Rac1, blocking the synthesis of the anti-apoptotic protein Bcl-xL, thereby inducing apoptosis (programmed cell death) in activated T cells and mononuclear cells, a phenomenon observed in inflammatory bowel disease patients treated with Azathioprine.
Chemistry
Chemical Structure & Properties
Azathioprine is a complex organic compound characterized as a thiopurine, which is chemically linked to a second heterocyclic ring, an imidazole derivative, via a thioether bond. In its pure form, it presents as a pale yellow solid with a slightly bitter taste. It exhibits a melting point ranging from 238 to 245 ยฐC. Its solubility profile is notable: it is practically insoluble in water and only sparingly soluble in lipophilic solvents such as chloroform, ethanol, and diethyl ether. However, it readily dissolves in alkaline aqueous solutions, where it undergoes hydrolysis to yield 6-mercaptopurine, its primary active metabolite.
Synthesis Pathway
The synthesis of Azathioprine involves a key reaction between 5-chloro-1-methyl-4-nitro-1H-imidazole and 6-mercaptopurine, typically carried out in a dimethyl sulfoxide solvent. The precursor, 5-chloro-1-methyl-4-nitro-1H-imidazole, is itself synthesized through a multi-step process. This begins with the formation of an amide from methylamine and diethyl oxalate. This amide then undergoes cyclization and subsequent chlorination using phosphorus pentachloride. Finally, a nitro group is introduced into the structure through a reaction involving nitric and sulfuric acids. This intricate synthetic route highlights the sophisticated chemical engineering required to produce this vital pharmaceutical compound.
History
Discovery & Initial Use
Azathioprine was first synthesized in 1957 by the pioneering pharmacologists George Herbert Hitchings and Gertrude Elion, who designated it as BW 57-322. Their initial objective was to create a metabolically active, yet "masked," form of 6-mercaptopurine (6-MP). Initially, Azathioprine was explored for its potential as a chemotherapy drug, leveraging its ability to interfere with DNA and RNA synthesis in rapidly dividing cells, a characteristic shared by many anticancer agents.
Immunosuppressive Breakthrough
A pivotal moment in Azathioprine's history came in 1958 when Robert Schwartz investigated the effects of 6-MP on the immune response. He discovered that 6-MP profoundly suppressed antibody formation in rabbits when co-administered with antigens, revealing its immunosuppressive properties. Building on this, and the foundational work by Sir Peter Medawar and Gertrude Elion on transplant rejection, Sir Roy Calne, a British transplantation pioneer, began experimenting with 6-MP as an immunosuppressant for kidney and heart transplants. When Calne sought related compounds, Elion suggested Azathioprine, which Calne subsequently found to be superior to 6-MP, offering comparable efficacy with reduced bone marrow toxicity.
Clinical Adoption & Evolution
The clinical breakthrough for Azathioprine occurred in April 1962, when regimens combining Azathioprine and prednisone enabled the first successful kidney allotransplantations to unrelated recipients. For many years, this dual therapy became the gold standard for antirejection treatment. However, the landscape of immunosuppression evolved with the introduction of cyclosporin into clinical practice by Calne in 1978. Cyclosporin, and later mycophenolate mofetil, have gradually replaced some of Azathioprine's use in organ transplantation due to their association with longer survival times, particularly in heart transplants, and generally fewer side effects such as bone marrow suppression and opportunistic infections, alongside a lower incidence of acute rejection, despite being considerably more expensive.
Teacher's Corner
Edit and Print this course in the Wiki2Web Teacher Studio
Click here to open the "Azathioprine" Wiki2Web Studio curriculum kit
Use the free Wiki2web Studio to generate printable flashcards, worksheets, exams, and export your materials as a web page or an interactive game.
True or False?
Test Your Knowledge!
Gamer's Corner
Are you ready for the Wiki2Web Clarity Challenge?
Unlock the mystery image and prove your knowledge by earning trophies. This simple game is addictively fun and is a great way to learn!
Play now
References
References
Feedback & Support
To report an issue with this page, or to find out ways to support the mission, please click here.
Disclaimer
Important Notice
This page was generated by an Artificial Intelligence and is intended for informational and educational purposes only. The content is based on a snapshot of publicly available data from Wikipedia and may not be entirely accurate, complete, or up-to-date.
This is not medical advice. The information provided on this website is not a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or medication, including Azathioprine. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
The creators of this page are not responsible for any errors or omissions, or for any actions taken based on the information provided herein.